BrainStorm appoints Bob Dagher as Chief Development Officer

BrainStorm Cell Therapeutics (BCLI) announced the appointment of Bob Dagher, as Executive Vice President and Chief Development Officer effective July 17. Dagher will serve on BrainStorm’s executive leadership team reporting to Stacy Lindborg, co-CEO of BrainStorm. He will be responsible for the portfolio strategy and advancement of clinical development plans towards regulatory approval, including the expansion of NurOwn into new diseases and the translation of pre-clinical research into first-in-human trials. Dagher joins BrainStorm from Enveric Biosciences (ENVB) where, as Chief Medical Officer, he was responsible for defining the portfolio strategy and advancement of development plans toward regulatory approvals. He began his career in biopharmaceuticals as a medical scientist at GSK (GSK), and has served in leadership positions of science and medicine at companies such as Sanofi/Genzyme, and LabCorp/Covance, for more than 20 years. Dagher earned his medical degree at Bordeaux University and St. Joseph University School of Medicine, serving residencies in psychiatry and internal medicine at Boston University Medical Center. A past Diplomat of the American Board of Neurology and Psychiatry, he is licensed to practice medicine in Massachusetts.